Mosley W H, Aziz K M, Mizanur Rahman A S, Alauddin Chowdhury A K, Ahmed A, Fahimuddin M
Bull World Health Organ. 1972;47(2):229-38.
A controlled cholera vaccine field trial was carried out in rural East Pakistan to determine the efficacy of a cholera vaccine of average antigenic potency when used in a continuing programme with annual reimmunizations. A cohort of 40 000 children aged 0-14 years was equally divided into a control group and 3 vaccine groups. Inoculations of vaccine were given annually for 3 years just before the start of the cholera season, and follow-up continued for 2 additional years. The results indicate that there was increasing protection with reimmunization, reaching a maximum with 3 doses. One dose produced 43% protection, 2 doses 64%, 3 doses 81%, and 4 doses 76%. Protection was more sustained after reimmunization; being 50% and 39%, 1 and 2 years after the fourth injection, respectively. Serological surveys suggested a general parallel in the antibody response to vaccine and the level of protection achieved; however, the levels of vibriocidal antibody titres could not be related directly to levels of protection. The overall protection achieved with the 3-year programme of annual reimmunizations was 55% for the group receiving one inoculation annually, and 65% for the group receiving 2 inoculations in the first year followed by annual reimmunizations. When the costs and effectiveness of annual vaccine programmes are compared with those for cholera treatment centres, it becomes clear that the cholera vaccines now available are not appropriate alternatives to treatment in routine cholera control programmes.
在东巴基斯坦农村地区开展了一项霍乱疫苗对照现场试验,以确定抗原效价一般的霍乱疫苗在每年进行再免疫的持续项目中使用时的效力。一组4万名0至14岁的儿童被平均分为一个对照组和3个疫苗组。在霍乱季节开始前,每年接种疫苗,持续3年,后续又持续随访了2年。结果表明,随着再免疫,保护作用不断增强,3剂时达到最大值。1剂产生43%的保护作用,2剂为64%,3剂为81%,4剂为76%。再免疫后保护作用更持久;在第四次注射后1年和2年时,保护率分别为50%和39%。血清学调查表明,对疫苗的抗体反应与所实现的保护水平总体呈平行关系;然而,杀弧菌抗体滴度水平与保护水平并无直接关联。对于每年接受1次接种的组,通过每年再免疫的3年项目所实现的总体保护率为55%,而对于第一年接受2次接种、随后每年再免疫的组,总体保护率为65%。当将每年疫苗项目的成本和效果与霍乱治疗中心的成本和效果进行比较时,很明显,现有的霍乱疫苗在常规霍乱控制项目中并非治疗的合适替代方法。